Lonza Inc.

Cambridge Enterprise Limited

Lonza Biologics Plc

Jesús Zurdo

Laurent Ducry

Fabrizio Chiti

Michele Vendruscolo

Laurence Bonnafoux

Andreas Arnell

Thomas Payne

Kateri Hayashi DuBay

Lars Arne Andreas Arnell

Ramon Gomez De La Cuesta

Rebecca Michael

Yvette Stallwood

Noel Hillier Smith

Christopher Dobson

José Jimenez

Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention.

CL and/or CH1 mutated antibodies for drug conjugation

The invention relates to methods of reducing the immunogenicity of CRISPR-associated (Cas) proteins and the modified Cas proteins produced therefrom. In addition, the invention relates to methods for cell and gene therapy, including any and all genetic modifications and alterations of gene expression (and/or genetic elements) made in-vivo or ex-vivo using Cas proteins with reduced immunogenicity.

CRISPR-associated (Cas) proteins with reduced immunogenicity

Antibodies

Growing community of inventors

Cambridgeshire, United Kingdom

Jesús Zurdo